Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17980908 | 1.00 | CTSK (0.53) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13636358 | 1.00 | CTSK (0.53) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12734596 | 0.89 | CTSK (0.61) | CTSKCTSS | |
| SCHEMBL12734600 | 0.89 | CTSK (0.61) | CTSKCTSS | |
| SCHEMBL15961701 | 0.89 | CTSK (0.61) | CTSKCTSS | |
| SCHEMBL24739376 | 0.87 | CTSK (0.56) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL28398590 | 0.87 | CTSK (0.56) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL24465592 | 0.87 | CTSK (0.56) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL4781261 | 0.86 | CTSK (0.55) | CTSKCTSSCA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL30306646 | 0.86 | CTSK (0.55) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372573-A | The synthesis technology of antihyperglycemic drug intermediate R-3- amino-piperadine dihydrochloride | 苏州汉德创宏生化科技有限公司 | 2019-10-25 | — | — | CN | claimed |
| EP-4423107-A1 | LIPID AMINES | ModernaTX, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-10787444-B2 | Compounds for the modulation of myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| CN-111471021-A | Substituted diaminocarboxamides and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-105001165-B | Substituted diaminopyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2020-06-23 | — | — | CN | disclosed |
| WO-2020115506-A1 | QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
| WO-2019238616-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |
| EP-3356340-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| WO-2017147335-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20140235533-A1 | DIHYDROFURAN DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| CN-101228182-A | Antibakterielle amid-makrozyklen v | AICURIS GMBH & CO KG (DE) | 2008-07-23 | — | — | CN | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| CN-101090909-A | Antibacterial amide macrocycles IV | AICURIS GMBH & CO KG (DE) | 2007-12-19 | — | — | CN | disclosed |
| CN-1882546-A | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | MERCK & CO INC (US) | 2006-12-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | CTSK 1179/4885CTSS 716/4885CA1 2709/4885 |
| US-20140235533-A1 | DIHYDROFURAN DERIVATIVES AS INSECTICIDAL COMPOUNDS | DDT, CBR3, HRH4 | CTSK 1723/4885CTSS 810/4885CA1 2838/4885 |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | CTSK 1821/4885CTSS 1342/4885CA1 3057/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | CTSK 1881/4885CTSS 2232/4885CA1 2950/4885 |
| US-10787444-B2 | Compounds for the modulation of myc activity | MYC, MYCBP, MYCBP2 | CTSK 1179/4885CTSS 716/4885CA1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.